Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.
In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Hosted on MSN7d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound ... its next-generation obesity drug retatrutide later this year, a few ...
We list the best Gantt chart software, to make it simple and easy to better visualize and manage progress when dealing with larges projects. Gantt chart software can be a powerful weapon in a ...
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback